

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Cost Comparison Appraisal**

# Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy ID4070

## **Final Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>BeiGene (tislelizumab)</li> <li>Patient/carer groups</li> <li>Black Health Agency for Equality</li> <li>Cancer 52</li> <li>Cancer Black Care</li> <li>Cancer Equality</li> <li>GIST Cancer UK</li> <li>GUTS UK</li> <li>Heartburn Cancer UK</li> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> <li>Ochre</li> <li>Oesophageal Patients Association</li> <li>OG Support formerly Together Support Group</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> </ul>	<ul> <li>General</li> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> <li>Welsh Health Specialised Services Committee</li> </ul> Comparator companies <ul> <li>Bristol Myers Squibb Pharmaceuticals (nivolumab)</li> </ul>
<ul> <li>Healthcare professional groups</li> <li>Association of Anaesthetists</li> <li>Association of Cancer Physicians</li> <li>Association of Surgeons of Great Britain and Ireland</li> <li>Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland</li> <li>British Association of Surgical Oncology</li> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> </ul>	Relevant research groups  Genomics England  Institute of Cancer Research  MRC Clinical Trials Unit  National Institute for Health Research  Associated Public Health groups  Public Health Wales  UK Health Security Agency

Final stakeholder list for the evaluation of tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy ID4070 Issue date: November 2024



<ul> <li>British Oncology Pharmacy Association</li> <li>British Psychosocial Oncology Society</li> <li>British Society of Gastroenterology</li> <li>Cancer Research UK</li> <li>Primary Care Society for Gastroenterology</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> </ul>	or appeal)
<ul> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the evaluation of tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy ID4070 Issue date: November 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.